ARUP Payroll Specialist Heather Oliver’s daughter Kara was diagnosed with Ewing sarcoma in late 2023. By sharing Kara’s story, Oliver hopes to inspire others to donate blood.
ARUP Laboratories is committed to helping clients and the clinical laboratory community navigate regulatory changes and is offering current resources and a new webinar.
ARUP Healthcare Advisory Services Manager David Shiembob has received the ADLM Clinical Laboratory Scientist Achievement Award, which recognizes significant contributions to the CLS community.
The inaugural event created connections among future innovators who look to solve many of healthcare’s biggest challenges.
This issue highlights milestones in ARUP’s history, gives a glimpse into the company’s future, and includes a special feature: a video of ARUP founders and current leaders reminiscing and celebrating.
Nicola Longo, who with his wife, Marzia Pasquali, is credited with expanding screening for a treatable metabolic disorder, is leaving for UCLA while Pasquali stays at ARUP to continue key projects.
Jan Wintch, CQA(ASQ), senior quality specialist, has worked at ARUP since the company’s inception. She enjoys her current role in Quality and remembers ARUP’s early years fondly.
ARUP Consult Updates Guidance on Testing for Autism Spectrum Disorder and Other Developmental Delays
The ARUP Consult Laboratory Testing for Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder topic now includes exome and genome sequencing as a first- or second-tier test.
Join ARUP in kickstarting Lab Week with a curated selection of podcasts, articles, and lectures that emphasize the important role medical lab professionals play in improving and saving patient lives.
ARUP to Showcase Neurology Laboratory Testing Menu at Upcoming American Academy of Neurology Meeting
ARUP medical directors and experts will be present to discuss the latest developments in neurology laboratory testing at the upcoming American Academy of Neurology (AAN) Annual Meeting.
The FDA’s proposed rule to regulate lab-developed tests will force labs to halt essential testing, harming children and patients with cancer and rare diseases, says ARUP’s Jonathan Genzen, MD, PhD.
ARUP’s new test, Alzheimer’s Disease Markers, CSF, will pave the way for more assays that help detect the disease soon enough to try therapy to slow its progression.